ADC Development Services Targeting CD71

Over the last decade, antibody-drug conjugates (ADCs) have emerged as one of the most promising new tools for the selective killing of tumor cells. ADCs can selectively deliver the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface molecules. CD71, a membrane glycoprotein expresses widely in cancer cells, has been regarded as an effective target in ADC therapy. As an acknowledged antibody preparation and ADCs construction services provider, Creative Biolabs provides ADCs development services targeting the CD71. Our professional scientists can not only save your valuable time but also provide highly sensitive and qualified products.

Introduction of CD71

CD71 (also known as transferring receptor protein 1), is a 95-kDa homodimeric transmembrane glycoprotein, which is encoded by the TFRC gene located on chromosome 3q29 in human. CD71 contains two disulfide-linked monomers linked via two disulfide bonds. A CD71 can bind two transferrins by two monomers, which forms an iron-Tf-TfR complex to facilitate iron uptake and the endocytosis of cells. Its expression is regulated depending on the cell’s iron need. CD71 is considered as a potential new target in many human cancers, such as the gastrointestinal malignancies..

Fig.1 Structure of the human CD71/H-Ft complex.

ADC Development Targeting CD71

ADCs are a kind of rapidly growing new anti-cancer therapeutic agents which may improve cancer patient survival. ADCs have significant advantages due to combining the specificity of tumour-antigen antibodies and the cytotoxicity of cytotoxic compounds. Currently, several ADCs have been designed to target the CD71 for the treatment of gastrointestinal malignancies. Clinical trials showed that these ADCs with obvious anti-tumor activity in the GI cancers.

AbGn-107 is an ADC targeting the CD71, which is composed of an anti-CD71 antibody linked to a cleavable linker-tubulin inhibitor. In pre-clinical trials, AbGn-107 showed superior antitumor efficacy in at least four established xenograft tumor models. Besides, the ADC presented safe and well-tolerable in non-human primates (NHP) toxicity studies. During the phase I trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AbGn-107 therapy in patients with chemo-refractory gastrointestinal malignancies, colorectal cancer and pancreatic cancers, the ADC also displayed significant potential. Thus, all these data indicated that AbGn-107 will be a promising therapy agent in the treatment of GI-related cancers.

Fig.2 The mechanism of ADCs therapy.

What Can We Do for You?

With our well-established antibody production and bio-conjugation platforms, Creative Biolabs provides world-class packaging services for the ADCs design and development targeting the CD71. Our ADCs development services include:

• ADC Antibody Screening
• DrugLnk™ Custom Synthesis
• Antibody Design and Conjugation
• ADC in vitro Analysis
• ADC in vivo Analysis

Our state-of-the-art facilities and highly experienced staffs are available to assist in all areas of ADCs design and generation in a quick turnaround. If you are interested in our service, please do not hesitate to contact us for more details.

For Research Use Only. NOT FOR CLINICAL USE.